RecruitingNCT05602610

Clinical Prognostic Score to Predict Relapse in VL

Comprehensive Clinical and Laboratory Assessment of Visceral Leishmaniasis to Develop Clinical Prognostic Tools to Predict Relapse: a Prospective Cohort Study in Ethiopia


Sponsor

Institute of Tropical Medicine, Belgium

Enrollment

741 participants

Start Date

Feb 3, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This prospective cohort study has the aim to develop a prognostic tool to predict relapse in patients suffering from visceral leishmaniasis (VL) from VL endemic regions in Ethiopia. Therefore, comprehensive clinical and laboratory characterization of all confirmed VL patients before and during treatment will be performed in order to identify the factors that determine prognosis of the patients. This approach would result in more efficient patient care and would reduce the case fatality and morbidity, and improve follow-up and care for those at risk of VL relapse.


Eligibility

Min Age: 12 Years

Inclusion Criteria1

  • clinically or parasitologically confirmed VL

Exclusion Criteria5

  • Age under 12 years
  • VL patients already on treatment for 3 days or more
  • Severe critical condition or other circumstances that make the study medically inadvisable
  • Unlikely to adhere to follow up visits during the study period (e.g. patients who live or work very far away) AND not reachable by phone for follow-up information
  • Pregnant or lactating woman

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention

No intervention


Locations(1)

University of Gondar

Gonder, Ethiopia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05602610